Using GE Healthcare’s single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, the team developed a new process for the production, clarification and concentration of cytomegalovirus-like particles. Results from
The SwRI technologies employ a controlled and continuous atomizing technology that Flexion believes may facilitate efficient scale-up of Phase III clinical trial material and commercial supply. The company
Apart from Norway, ILUVIEN is now approved for marketing in Austria, France, Germany, Italy, Portugal, Spain and the UK, and is commercially available in the UK and Germany.
As part of the deal, Lion has licensed from Moffitt the rights to develop and commercialize new technologies to improve TIL production from melanoma, which may be applicable
The CHMP recommendation of OZURDEX (dexamethasone 700mcg intravitreal implant in applicator) is for DME patients who are pseudophakic (have an artificial lens implant), or who are considered insufficiently
The Phase II trial is designed to assess the safety, tolerability and efficacy of RTA 408 Lotion versus vehicle for the prevention and treatment of radiation dermatitis in
According to the companies, the Phase III trial called RESILIENCE failed to meet its primary endpoint of improving progression-free survival (PFS). In the randomized, double-blind, placebo-controlled trial, the
The CHMP recommendation for Imbruvica is to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukemia (CLL) who have
The deal will see the development and scale-up of a new affinity resin and associated manufacturing process to improve the quality and purity of an existing biopharmaceutical product
The multicenter, randomized, placebo-controlled Phase II trial will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant CMV infection in adult 18 years and older.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.